Skip to main content
  • Novel Tricuspid Valve Replacement Device Shows Favorable Outcomes for TR: TRISCEND Trial

    Transfemoral tricuspid valve replacement with the novel EVOQUE system has favorable 30-day and 6-month outcomes in patients with tricuspid regurgitation (TR), new trial data report.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details